Cardio Diagnostics Holdings, Inc. (CDIO) stock
Close on Nov 11, 2026Market cap $5.68MP/E –Yield –
Cardio Diagnostics Holdings, Inc. reported revenue of $15.19K for the twelve months to Sep 30, 2026. Free cash flow was -$5.78M. At the latest close the market valued the company at $5.68M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $5.68M
- P/E ratio
- –
- Price to sales
- 374.20
- Price to book
- 0.99
- Dividend yield
- –
- Free cash flow yield
- -101.79%
Fundamentals
- Revenue
- $15.19K
- Net income
- -$6.49M
- EPS, diluted
- -$2.53
- Free cash flow
- -$5.78M
- Book value per share
- $1.93
- Diluted shares
- 3M
Trading
- Previous close
- $1.86
- Open
- $1.86
- Day's range
- $1.86 – $1.96
- Volume
- 9,617
- Average volume (20 days)
- 16,801
- Beta (5 years)
- 2.65
- 52-week range
- $0.97 – $7.91
- RSI (14 days)
- 61.1
- Volatility (1 year)
- 147.8%
- Relative volume
- 0.21×
- WACC
- 17.4%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CDIO | S&P 500 | Difference | CDIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.7% | -2.4% | +5.1 pts | ||
| 3 months | +4.9% | -1.2% | +6.1 pts | ||
| Year to date | -29.2% | +12.3% | −41.4 pts | ||
| 1 year | -49.6% | +12.4% | −62.1 pts | ||
| 3 years | -93.7% | +78.8% | −172.5 pts | -60.3% | +21.4% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cardio Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- News
About Cardio Diagnostics
In Vitro & In Vivo Diagnostic Substances
Cardio Diagnostics Holdings, Inc. develops and commercializes artificial intelligence-driven, epigenetics-based clinical blood tests and platforms for cardiovascular disease. The company's core product offerings include Epi+Gen CHD, a test designed to assess the three-year risk of symptomatic coronary heart disease events, and PrecisionCHD, a test used to detect coronary heart disease alongside actionable clinical intelligence. In addition, the firm offers HeartRisk, a cardiovascular risk intelligence platform, and CardioInnovate360, a research-use-only tool supporting biopharmaceutical discovery and development. Its diagnostic solutions serve patients, healthcare providers, health systems, self-insured employers, and payors.
Company profile, executives and historyCardio Diagnostics stock: common questions
What is Cardio Diagnostics's stock price?
CDIO closed at $1.92 on Nov 11, 2026, up 3.23% on the day. Over the past 52 weeks it traded between $0.97 and $7.91.
What is Cardio Diagnostics's market cap?
Cardio Diagnostics was worth $5.68M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CDIO's P/E ratio?
Cardio Diagnostics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.53), so it has no meaningful P/E ratio.
How much revenue does Cardio Diagnostics make?
Cardio Diagnostics reported revenue of $15.19K for the twelve months to Sep 30, 2026.
Does Cardio Diagnostics pay a dividend?
No. Cardio Diagnostics has not paid a cash dividend over the last twelve months.
How has CDIO stock performed over the past year?
Including dividends, CDIO returned -49.6% over the past year, against +12.4% for the S&P 500.
Who are Cardio Diagnostics's competitors?
Companies most similar to Cardio Diagnostics by business, industry and size include VRAX, AWHL, PRFX, BDPT, SNTI.
See a number that looks wrong?